Homology Medicines Inc. shared its Q3 2023 results, showing a net loss of $33.0 million. The genetic medicines company has halted all of its programs due to the current financial climate and the expected clinical development timeline. This includes its HMI-103 gene editing candidate for the treatment of phenylketonuria (PKU). The company, which said it has enough cash to fund operations for a year, is now evaluating its strategic options and has retained TD Cowen as its strategic financial advisor.
New EU Commission to come up with healthcare cybersecurity plan
The European Commission’s new focus will be strengthening the EU’s healthcare sector against cyber-attacks, with a 100-day plan to initiate implementation of cybersecurity regulations. Cost
